Shopping Cart
Remove All
Your shopping cart is currently empty
Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF with IC50 values of 56, 7, and 5 nM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $42 | In Stock | In Stock | |
| 5 mg | $98 | In Stock | In Stock | |
| 10 mg | $172 | In Stock | In Stock | |
| 25 mg | $347 | In Stock | In Stock | |
| 50 mg | $519 | In Stock | In Stock | |
| 100 mg | $787 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $98 | In Stock | In Stock |
| Description | Belvarafenib (HM95573) is a potent pan-RAF inhibitor with antitumor activity and inhibits B-RAF, B-RAFv600E, and C-RAF with IC50 values of 56, 7, and 5 nM. |
| Targets&IC50 | B-Raf (V600E):7 nM, B-Raf:56 nM, C-Raf:5 nM |
| In vitro | Belvarafenib (HM95573) inhibited B-RAF, B-RAFv600E and C-RAF with IC50 values of 56, 7 and 5 nM, respectively.[1] |
| In vivo | METHODS: Data were collected from 192 patients with melanoma who underwent NGS between November 2017 and May 2023.EAP patients were treated with 450 mg of Belvarafenib (HM95573) twice daily. RESULTS Six patients with NRAS or RAF alterations were treated with Belvarafenib (HM95573), and 50% of the patients had control of their disease, including two patients with significant outcomes. [2] |
| Molecular Weight | 478.93 |
| Formula | C23H16ClFN6OS |
| Cas No. | 1446113-23-0 |
| Smiles | Cc1ccc2c(Nc3cccc(Cl)c3F)nccc2c1NC(=O)c1csc2c(N)ncnc12 |
| Relative Density. | 1.562 g/cm3 (Predicted) |
| Color | Yellow |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (52.2 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.09 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.